alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 151–175 of 204 studies scoring ≥ 67 out of 100 published 2023 (page 7 of 9) · 30,980 in the whole library · How the 0–100 score works

Download bibliography of these 204 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,452 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios

✓ Peer-reviewed alzhub usefulness score 69 out of 100. JAMA neurology 2023-05-01

Higher eGFR was associated with increased levels of plasma p-tau217, p-tau181, Tau212-221, and Tau181-190 in individuals with cognitive impairment (cohort 1: R range, -0.24 to -0.59; P Conclusions and relevance In this study, CKD was associated with increased plasma levels of soluble tau, but for p-tau217 the associations were considerably lower than the association with Aβ positivity. 4 key findings →

Design: cross-sectional Participants: 141 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Patterns of Regional Brain Atrophy and Brain Aging in Middle- and Older-Aged Adults With Type 1 Diabetes

✓ Peer-reviewed alzhub usefulness score 69 out of 100. JAMA network open 2023-06-01

EDIC participants had consistently higher brain age values compared with controls without diabetes, indicative of approximately 6 additional years of brain aging (EDIC participants: β, 6.16; SE, 0.71; control participants: β, 1.04; SE, 0.04; P Conclusions and relevance The findings of this study suggest an increase in brain aging among individuals with T1D without any early signs of AD-related neurodegeneration. 4 key findings →

Design: cohort study Participants: 416 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Association of Sleep-Disordered Breathing and Medial Temporal Lobe Atrophy in Cognitively Unimpaired Amyloid-Positive Older Adults

✓ Peer-reviewed alzhub usefulness score 69 out of 100. Neurology 2023-05-31

Overall, we showed that SDB was associated with MTL atrophy in cognitively asymptomatic older adults engaged in the Alzheimer continuum, which may increase the risk of developing memory impairment over time. 3 key findings →

Design: randomized controlled trial Participants: 122 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Association of New Use of Antihypertensives That Stimulate vs Inhibit Type 2 and 4 Angiotensin II Receptors With Dementia Among Medicare Beneficiaries

✓ Peer-reviewed alzhub usefulness score 69 out of 100. JAMA network open 2023-01-03

This cohort study of Medicare beneficiaries suggests that use of antihypertensive medications that stimulate type 2 and 4 angiotensin II receptors was associated with lower risk of ADRD compared with antihypertensive medications that inhibit these receptors. 5 key findings →

Design: randomized controlled trial Participants: 57 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Efficacy and Safety of Cilostazol in Mild Cognitive Impairment: A Randomized Clinical Trial

✓ Peer-reviewed alzhub usefulness score 69 out of 100. JAMA network open 2023-12-01

The full analysis set included 159 patients (66 [41.5%] male; mean [SD] age, 75.6 [5.2] years) who received placebo or cilostazol at least once. 2 key findings →

Design: clinical trial Participants: 159 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity

✓ Peer-reviewed alzhub usefulness score 69 out of 100. JAMA neurology 2023-10-01

An increased tau positron emission tomography (PET) signal in the medial temporal lobe (MTL) has been observed in older individuals in the absence of amyloid-β (Aβ) pathology. 4 key findings →

Design: cohort study Participants: 1,093 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Peripherin is a biomarker of axonal damage in peripheral nervous system disease

✓ Peer-reviewed alzhub usefulness score 69 out of 100. Brain : a journal of neurology 2023-11-01

We demonstrated that peripherin is distributed in sciatic nerve, and to a lesser extent spinal cord tissue lysates, but not in brain or extra-neural tissues. 3 key findings →

Design: longitudinal study Participants: 45 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Plasma phosphorylated tau-217 exhibits sex-specific prognostication of cognitive decline and brain atrophy in cognitively unimpaired adults

✓ Peer-reviewed alzhub usefulness score 69 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2023-08-28

Plasma p-tau217 may capture earlier Alzheimer's disease (AD)-related cognitive and brain atrophy hallmarks in females compared to males, possibly reflective of increased susceptibility to AD pathophysiology. 2 key findings →

Design: longitudinal study Participants: 163 Evidence: moderate

Full summary, score breakdown and related studies → Original source

The effects of COVID-19 on cognitive performance in a community-based cohort: a COVID symptom study biobank prospective cohort study

✓ Peer-reviewed alzhub usefulness score 69 out of 100. EClinicalMedicine 2023-07-21

Stratification by self-reported recovery revealed that deficits were only detectable in SARS-CoV-2 positive individuals who did not feel recovered from COVID-19, whereas individuals who reported full recovery showed no deficits. 2 key findings →

Design: cohort study Participants: 1,737 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Profiling post-COVID-19 condition across different variants of SARS-CoV-2: a prospective longitudinal study in unvaccinated wild-type, unvaccinated alpha-variant, and vaccinated delta-variant populations

✓ Peer-reviewed alzhub usefulness score 69 out of 100. The Lancet. Digital health 2023-05-16

These three main clusers were confirmed in a testing sample. 5 key findings →

Design: cohort study Participants: 9,804 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Comparison of Particulate Air Pollution From Different Emission Sources and Incident Dementia in the US

✓ Peer-reviewed alzhub usefulness score 69 out of 100. JAMA internal medicine 2023-10-01

In this cohort study, higher residential PM2.5 levels, especially from agriculture and wildfires, were associated with higher rates of incident dementia, providing further evidence supporting PM2.5 reduction as a population-based approach to promote healthy cognitive aging. 5 key findings →

Design: cohort study Participants: 27 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi-cohort study

✓ Peer-reviewed alzhub usefulness score 69 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2023-01-17

P-tau/Aβ42 is sufficient for predicting progression in AD, with very high accuracy. 1 key finding →

Design: longitudinal study Participants: 1,983 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Harmonization of CSF and imaging biomarkers in Alzheimer's disease: Need and practical applications for genetics studies and preclinical classification

✓ Peer-reviewed alzhub usefulness score 69 out of 100. Neurobiology of disease 2023-12-09

In Alzheimer's disease (AD) research, cerebrospinal fluid (CSF) Amyloid beta (Aβ), Tau and pTau are the most accepted and well validated biomarkers. 3 key findings →

Design: meta-analysis Evidence: high

Full summary, score breakdown and related studies → Original source

Peripheral immune cell imbalance is associated with cortical beta-amyloid deposition and longitudinal cognitive decline

✓ Peer-reviewed alzhub usefulness score 69 out of 100. Scientific reports 2023-05-31

Neuroinflammation is believed to be a key process in Alzheimer's disease (AD) pathogenesis. 5 key findings →

Design: longitudinal study Participants: 1,544 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Association of Chronic Kidney Disease With Plasma NfL and Other Biomarkers of Neurodegeneration: The H70 Birth Cohort Study in Gothenburg

✓ Peer-reviewed alzhub usefulness score 68 out of 100. Neurology 2023-05-24

In a community-based cohort of 70-year olds, P-NfL was associated with both prevalent and incident CKD, while CSF and/or imaging measures did not differ by CKD status. 3 key findings →

Design: cohort study Participants: 744 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial

✓ Peer-reviewed alzhub usefulness score 68 out of 100. JAMA neurology 2023-12-01

In this randomized clinical trial, BIIB080 reduced tau biomarkers, including CSF t-tau, CSF p-tau181, and tau PET, which is associated with cognitive decline, in participants with mild AD. 5 key findings →

Design: clinical trial Participants: 13 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Association of social isolation and loneliness with risk of incident hospital-treated infections: an analysis of data from the UK Biobank and Finnish Health and Social Support studies

✓ Peer-reviewed alzhub usefulness score 68 out of 100. The Lancet. Public health 2023-01-17

Although loneliness and social isolation have been linked to an increased risk of non-communicable diseases such as cardiovascular disease and dementia, their association with the risk of severe infection is uncertain. 4 key findings →

Design: cohort study Participants: 905 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Plasma-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms: A community-based study

✓ Peer-reviewed alzhub usefulness score 68 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2023-07-30

P-tau181 (odds ratio [OR] 2.06, 95% confidence interval [CI] 1.41-3.00, p < 0.001), p-tau217 (OR 1.70, 95% CI 1.10-2.61, p = 0.016), and t-tau (OR 1.44, 95% CI 1.08-1.92, p = 0.012) were associated with appetite change. 5 key findings →

Design: cross-sectional Participants: 1,005 Evidence: low

Full summary, score breakdown and related studies → Original source

Enlarged perivascular spaces and plasma Aβ42/Aβ40 ratio in older adults without dementia

✓ Peer-reviewed alzhub usefulness score 68 out of 100. Neurobiology of aging 2023-04-14

Dilation of perivascular spaces (PVS) in the brain may indicate poor fluid drainage due to the accumulation of perivascular cell debris, waste, and proteins, including amyloid-beta (Aβ). 2 key findings →

Design: longitudinal study Participants: 56 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Liver-Specific Polygenic Risk Score Is Associated with Alzheimer's Disease Diagnosis

✓ Peer-reviewed alzhub usefulness score 68 out of 100. Journal of Alzheimer's disease : JAD 2023

The AD PRS model that was most predictive of AD diagnosis (even without APOE) was the liver AD PRS: n = 1,115; odds ratio = 2.15 (1.67-2.78), p = 3.62×10-9. 3 key findings →

Design: cohort study Participants: 1,115 Evidence: moderate

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,040 records (3.4% of the library) are not peer-reviewed — 965 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events